PlainRecalls
FDA Drug Moderate Class II Terminated

Anastrozole Tablets, USP, 1 mg, a) 30-count (NDC 68001-155-04) and 1000-count (NDC 68001-155-08) bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories

Reported: July 17, 2019 Initiated: May 9, 2019 #D-1467-2019

Product Description

Anastrozole Tablets, USP, 1 mg, a) 30-count (NDC 68001-155-04) and 1000-count (NDC 68001-155-08) bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories

Reason for Recall

GMP Deviations: Potential cross contamination due to cleaning procedure failure.

Details

Recalling Firm
American Health Packaging
Units Affected
375,921 bottles
Distribution
Nationwide USA
Location
Columbus, OH

Frequently Asked Questions

What product was recalled?
Anastrozole Tablets, USP, 1 mg, a) 30-count (NDC 68001-155-04) and 1000-count (NDC 68001-155-08) bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories. Recalled by American Health Packaging. Units affected: 375,921 bottles.
Why was this product recalled?
GMP Deviations: Potential cross contamination due to cleaning procedure failure.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 17, 2019. Severity: Moderate. Recall number: D-1467-2019.